[{"indications": "Indications\u00a0see under Dose", "name": "SOMATROPIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.5 Hypothalamic and pituitary hormones and anti-oestrogens", "6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens", "Anterior pituitary hormones", "Growth hormone", "SOMATROPIN"], "cautions": "Cautions\u00a0diabetes mellitus (adjustment of antidiabetic\r\ntherapy may be necessary), papilloedema (see under Side-effects), relative deficiencies of\r\nother pituitary hormones (notably hypothyroidism\u2014manufacturers recommend periodic thyroid function tests but limited\r\nevidence of clinical value), history of malignant disease, disorders of the epiphysis of the hip (monitor for\r\nlimping), resolved intracranial hypertension\r\n(monitor closely), initiation of treatment\r\nclose to puberty not recommended in child born small for gestational\r\nage; Silver-Russell syndrome; rotate subcutaneous injection sites to prevent lipoatrophy; interactions: Appendix 1 (somatropin)", "side-effects": "Side-effects\u00a0headache, funduscopy for papilloedema recommended\r\nif severe or recurrent  headache, visual problems, nausea and vomiting\r\noccur\u2014if papilloedema confirmed consider benign intracranial hypertension\r\n(rare cases reported); fluid retention (peripheral oedema), arthralgia,\r\nmyalgia, carpal tunnel syndrome, paraesthesia, antibody formation,\r\nhypothyroidism, insulin resistance, hyperglycaemia, hypoglycaemia,\r\nreactions at injection site; leukaemia in children with growth hormone\r\ndeficiency also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4414.htm", "doses": ["Gonadal dysgenesis (Turner syndrome), by subcutaneous\r\ninjection, 45\u201350\u00a0micrograms/kg daily or 1.4\u00a0mg/m2 daily", "Deficiency of growth hormone in children, by subcutaneous or intramuscular injection, 23\u201339\u00a0micrograms/kg\r\ndaily or 0.7\u20131\u00a0mg/m2 daily", "Growth disturbance in short children born small for gestational\r\nage whose growth has not caught up by 4 years or later, by\r\nsubcutaneous injection, 35\u00a0micrograms/kg daily or 1\u00a0mg/m2 daily", "Prader-Willi syndrome, by subcutaneous injection in children with growth velocity greater than 1\u00a0cm/year, in combination\r\nwith energy-restricted diet, 35\u00a0micrograms/kg daily or 1\u00a0mg/m2 daily; max. 2.7\u00a0mg daily", "Chronic renal insufficiency in children (renal function decreased\r\nto less than 50%), by subcutaneous injection, 45\u201350\u00a0micrograms/kg\r\ndaily or 1.4\u00a0mg/m2 daily (higher doses\r\nmay be needed) adjusted if necessary after 6 months", "Adult growth hormone deficiency, by subcutaneous injection, initially 150\u2013300\u00a0micrograms daily, gradually increased if required\r\nto max. 1\u00a0mg daily; use minimum effective dose (requirements may decrease\r\nwith age)", "SHOX deficiency in children, by subcutaneous injection, 45\u201350\u00a0micrograms/kg daily", "Dose formerly expressed in units; somatropin 1\u00a0mg \u2261 3\u00a0units"], "pregnancy": "Pregnancy\u00a0discontinue if pregnancy occurs\u2014no information available"}]